GSK, Pfizer and Shionogi have agreed on changes to the structure of minority shares in ViiV Healthcare.[1][2] Shionogi will increase its stake from 10% to 21.7% by buying new shares for US$2.125 billion.[1][3][4] Pfizer will sell its 11.7% stake for $1.875 billion or $1.88 billion.[1][2] GSK will retain a majority stake of 78.3%.[1][2][4] ViiV Healthcare cancels Pfizer shares and pays GSK a special dividend of US$250 million.[1][2] The transaction should be completed in the first quarter of 2026, possibly by the end of March, after receiving regulatory approvals.[1][3][4] ViiV Healthcare is an HIV drug company founded by GSK and Pfizer in 2009, with Shionogi joining in 2012.[2][5] The deal simplifies the ownership structure of the company, which develops long-acting injectable drugs to treat and prevent HIV.[2]